AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

FRANCIS LAURA sold $1.1M of SIBN (indirect holdings)

FRANCIS LAURA (Chief Executive Officer) sold 55,807 indirectly-held shares of SI-BONE, Inc. (SIBN) at an average of $19.50 ($19.46–$20.02, $1.09M total) across 2 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FRANCIS LAURA
Published Aug 21, 2026, 9:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate market impact.

02

Market read

Insider sell adds to routine monitoring data; unlikely to drive significant price movement.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

CEO Laura Francis sold 55,807 shares for $1.09M via a 10b5‑1 plan, reducing her stake to 317,463 shares.

Expected impact

Minor downward pressure, likely within normal volatility range.

Evidence & confidence

Sale size is modest relative to float and disclosed under a pre‑arranged plan, reducing informational value.

Market effects

Sector

Minimal impact on orthopedic device sector; no broader industry signal.

Regional

No regional effect; company is US‑based with limited market exposure.

Global

Negligible global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal; price may remain stable.

Key entities

  • Executive
    Laura Francis

    Chief Executive Officer of SI‑BONE, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com